糖尿病性黄斑水肿的治疗进展  

Current research of diabetic macular edema

作　　者：林琳[1] 盛艳娟(综述)[1] 王玉(审校)[1] 

机构地区：[1]济南市第二人民医院眼科,250001

出　　处：《中华实验眼科杂志》2013年第10期992-996,共5页Chinese Journal Of Experimental Ophthalmology

摘　　要：糖尿病性黄斑水肿（DME）是糖尿病患者视力丧失的首要原因，根据DME的严重程度及水肿类型、选择合适的治疗方式对于挽救患者的视力至关重要。目前，DME的治疗方法包括激光光凝、糖皮质激素的应用、抗血管内皮生长因子（VEGF）药物的玻璃体内注射、蛋白激酶C抑制剂的应用、玻璃体手术及联合治疗方法等，但每种疗法都有其优点和不足。激光光凝、玻璃体手术以及玻璃体腔内注药和植入药物缓释系统均为破坏性治疗方式，对已损坏的视网膜光感受器的功能和结构无法挽救，因此应尽早发现和诊断DME，尽量选择创伤小、不良反应少的治疗方法进行干预。本文对DME治疗的国内外研究现状及未来的发展趋势进行综述。Diabetic macular edema （DME） is a teading cause of vision loss in diabetic patients. It is very important to correctly select a treating approach for DME. At present, the treating methods of DME include retinal laser photocoagulation,application of the glucocorticoid, intravitreous injection of anti-vascular endothelial growth factor （VEGF） drugs, administration of inhibitor of protein kinase C, vitrectomy and combined treatment etc. However, each method has its advantage and disadvantage. Retinal photocoagulation, vitrectomy, intravitreous injection and drug delivery system implantation are invasive treatment methods,and they can not rescue damaged retinal photoreceptors. Therefore,it is recommended that DME should be early diagnosed and effective treatment. The research status at home and abroad and future development trends of DME treatment were summarized.

关 键 词：糖尿病 并发症 黄斑水肿 视网膜 激光光凝 药物缓释系统 玻璃体切割 

分 类 号：R587.2[医药卫生—内分泌]